MicroStockHub/iStock via Getty Images
Edgewise Therapeutics (NASDAQ:EWTX) was downgraded to Sector Perform from prior Sector Outperform at Scotiabank after results from the company’s mid-stage trial for its heart disease, hypertrophic cardiomyopathy.
Stock down about 17% in morning trade.
Although a lot of the data
